Key Facts
✔ HILT operates at significantly higher power than standard laser therapy - enabling deeper tissue penetration without surface damage
✔ A 2023 systematic review and meta-analysis of 48 RCTs found HILT effective for pain reduction and functional improvement across multiple musculoskeletal conditions
✔ The strongest evidence exists for knee osteoarthritis, neck pain, shoulder pathology and lateral epicondylitis
✔ HILT is a treatment modality - not a standalone cure - and works best as part of a structured physiotherapy protocol
✔ At RheCore, equipment selection and treatment parameters are determined by clinical assessment, not by a fixed protocol applied to every patient

30-Second Summary

High-intensity laser therapy is a photobiomodulation modality that delivers energy at a depth and intensity that standard laser devices cannot reach. The evidence base - now spanning multiple systematic reviews and meta-analyses - supports its use for specific musculoskeletal conditions when applied with appropriate parameters and integrated into a broader physiotherapy treatment plan. This article outlines the mechanism, the evidence by condition, and how we approach its clinical application at RheCore.

Introduction: Why Equipment Specification Matters

Not all laser therapy is the same. This is a point that gets obscured in both clinical conversations and marketing, and it matters - because the therapeutic effect of laser is directly tied to the power output, wavelength, energy density and application technique used.

High-intensity laser therapy (HILT) operates in a different category from low-level laser therapy (LLLT). Where LLLT typically delivers energy in the milliwatt range at superficial tissue depths, HILT operates at wattage levels - commonly between 8 and 25 watts - with wavelengths in the 1064 nm range that penetrate significantly deeper into musculoskeletal tissue. This distinction is not merely technical. It determines which conditions are appropriate for treatment and what outcomes are clinically achievable.

At RheCore, the decision to invest in BTL high-intensity laser equipment followed a review of the emerging evidence base, not a preference for novel technology. The question we asked was straightforward: for which conditions does the research demonstrate meaningful clinical benefit, and under which application parameters? This article shares that evidence transparently.

The Mechanism: How HILT Works

HILT exerts its therapeutic effect through photobiomodulation - the interaction of laser energy with biological tissue at a cellular level. The primary mechanisms relevant to musculoskeletal care are:

Anti-inflammatory effect: Laser irradiation at therapeutic intensities reduces pro-inflammatory cytokines including IL-1β, IL-8 and TNF-α, while suppressing peripheral nociceptors and modulating the inflammatory cascade at the tissue level.

Analgesic effect: HILT stimulates the release of endogenous endorphins and serotonin, inhibits A-delta and C fibre pain transmission, and elevates the pain threshold at the treatment site. These are not indirect effects - they are the primary drivers of the pain relief that patients experience.

Tissue regeneration: At the cellular level, HILT enhances mitochondrial activity, increases ATP production, promotes collagen synthesis and accelerates tissue repair. For chronic tendinopathy and soft tissue injuries, this regenerative pathway is clinically relevant.

Deep penetration: The 1064 nm wavelength used in HILT penetrates significantly deeper than shorter wavelengths used in standard laser therapy - reaching joints, deeper muscle groups and structures that surface-level treatments cannot adequately address.

The depth advantage is not theoretical. It is why HILT has been studied specifically for conditions involving deep tissue structures - knee osteoarthritis, lumbar musculature, shoulder rotator cuff, and cervical structures - where surface-level energy delivery is insufficient.

What the Evidence Shows - by Condition

The following is an honest summary of the current evidence base. We present what the research supports, where the evidence is stronger, and where caution is appropriate.

Neck Pain - Strong Evidence

The evidence for HILT in neck pain is among the most robust in the literature.

A 2023 systematic review and meta-analysis published in Physiotherapy - the journal of the Australian Physiotherapy Association - analysed 8 RCTs and found HILT produced a standardised mean difference of 2.12 for pain intensity reduction compared with placebo or control interventions. This is a clinically meaningful effect size. The review found the most favourable results were obtained when HILT addressed myofascial pain, cervical radiculopathy and chronic neck pain.

A 2024 systematic review published in Lasers in Medical Science confirmed these findings, concluding that HILT is effective for reducing pain, disability and improving range of movement in patients with neck pain - with the strongest results in myofascial and radiculopathy presentations.

Clinical implication at RheCore: For patients presenting with chronic neck pain, cervicogenic headache, or neck pain with referred arm symptoms where deeper tissue involvement is suspected, HILT is considered as part of the treatment plan following clinical assessment.

Knee Osteoarthritis - Strong Evidence

HILT and LLLT combined with exercise therapy have emerged as effective treatment options for musculoskeletal pain, particularly in knee osteoarthritis. A 2024 systematic review and network meta-analysis published in PMC covering evidence through December 2023 confirmed that HILT combined with exercise therapy produced clinically significant improvements in pain and physical function in knee osteoarthritis patients.

An RCT comparing HILT against ibuprofen gel phonophoresis in knee osteoarthritis found HILT produced significantly greater improvements in pain, stiffness and physical function - with the HILT group demonstrating statistically superior outcomes on validated outcome measures.

A broader 2023 systematic review of HILT across musculoskeletal disorders - covering 48 RCTs - found particularly improved functionality outcomes for knee and shoulder conditions when compared to other anatomical regions.

Clinical implication at RheCore: For patients with confirmed knee osteoarthritis who have not responded adequately to exercise therapy alone, HILT is considered as an adjunct treatment aimed at reducing pain sufficiently to enable better engagement with strengthening and rehabilitation. The research consistently supports HILT as part of a combined protocol - not as a replacement for exercise-based rehabilitation.

Shoulder Pathology - Moderate to Strong Evidence

Differences in the effectiveness of HILT were found depending on anatomical location, with further improved functionality in musculoskeletal disorders of the knee and shoulder.

The evidence for shoulder conditions spans subacromial impingement syndrome, rotator cuff pathology and frozen shoulder. Multiple RCTs have demonstrated HILT produces superior short-term outcomes for pain and functional recovery compared with control interventions in shoulder presentations. The deep penetration capacity of HILT is particularly relevant here - the rotator cuff and subacromial structures are not well reached by surface-level modalities.

Clinical implication at RheCore: Shoulder presentations - particularly those involving chronic rotator cuff irritation, impingement or restricted mobility - are assessed for HILT suitability based on chronicity, depth of tissue involvement and response to initial manual therapy and exercise.

Lower Back Pain - Evidence with Nuance

The evidence for HILT in lower back pain requires honest qualification, which is why we present it differently from the conditions above.

An RCT published in Evidence-Based Complementary and Alternative Medicine (Abdelbasset et al., 2020) randomised 60 patients with chronic non-specific lower back pain to HILT, LLLT or control. Both laser therapy groups showed statistically significant improvements in the Oswestry Disability Index, VAS pain scores, lumbar range of motion and European Quality of Life scores compared to control. However - and this is the important finding - there was no statistically significant difference between HILT and LLLT when compared directly.

This finding does not mean HILT is ineffective for lower back pain. It means the comparative advantage of HILT over lower-intensity laser therapy has not been clearly established for this condition in the available research. Laser therapy works for chronic lower back pain - the form of laser is less clearly differentiated.

A 2023 systematic review and meta-analysis covering 48 RCTs confirmed HILT is effective for improving pain, functionality, range of motion and quality of life in people with musculoskeletal disorders, although these findings must be treated with caution due to the high risk of bias in the studies.

Clinical implication at RheCore: For lower back pain, HILT is not our default adjunct modality. Clinical assessment determines whether the depth and anti-inflammatory capacity of HILT adds meaningful value for a given patient - particularly those with deeper lumbar muscle involvement, facet irritation or nerve-related presentations where deeper energy delivery may be advantageous.

Lateral Epicondylitis (Tennis Elbow) - Emerging Evidence

A systematic review and meta-analysis specifically examining HILT for lateral epicondylitis found improvements in disability, pain, grip strength and quality of life. This is a condition where HILT's capacity to penetrate deeper connective tissue is clinically relevant - particularly for chronic, resistant presentations that have not responded to standard management.

Clinical implication at RheCore: For persistent lateral epicondylalgia that has not responded to graded loading exercise, HILT is considered as a treatment adjunct - consistent with the evidence supporting its use in tendinopathy management.

How We Apply HILT at RheCore: The Protocol Matters

The research is consistent on one point across all conditions: HILT works best when applied as part of a structured physiotherapy protocol, not as an isolated treatment.

The parameters that determine clinical outcomes - power output, wavelength, energy density, application duration and frequency - are not fixed. They are calibrated to the condition, the patient's presentation and the treatment phase. Applying the same laser protocol to a chronic knee osteoarthritis presentation and an acute neck sprain would be clinically inappropriate. The equipment enables the treatment - the physiotherapist determines whether it is indicated, at what parameters, and within what broader plan.

At RheCore, HILT is considered at the clinical assessment stage, not as a default add-on. Patients who receive HILT as part of their management plan will also receive manual therapy, targeted exercise prescription and education - because the evidence base does not support laser therapy as a standalone intervention for any of the conditions described above.

For Clinicians Considering Referral

For referring practitioners - GPs, orthopaedic surgeons and specialists - the following summarises the clinical profile of patients for whom HILT at RheCore is most likely to be appropriate:

• Chronic musculoskeletal presentations (greater than 3 months) that have not fully responded to standard conservative management
• Knee osteoarthritis with ongoing pain limiting rehabilitation engagement
• Chronic neck pain including myofascial and cervicogenic presentations
• Shoulder pathology involving rotator cuff or subacromial structures
• Persistent tendinopathy (lateral epicondylalgia, Achilles, patellar) resistant to loading programs
• Presentations where deeper tissue anti-inflammatory effect is clinically desirable

HILT is not indicated as a standalone treatment, is not a substitute for exercise-based rehabilitation, and is not appropriate for all presentations. Clinical assessment determines suitability.

Key Takeaways

• HILT is a high-power photobiomodulation modality with documented anti-inflammatory, analgesic and tissue-regeneration mechanisms
• The strongest evidence supports its use in neck pain, knee osteoarthritis, shoulder pathology and lateral epicondylitis
• For lower back pain, laser therapy is effective - but HILT's comparative advantage over lower-intensity laser is not yet clearly established
• Equipment specification matters: power, wavelength and energy density determine clinical outcomes, not the technology label alone
• At RheCore, HILT is applied within a structured physiotherapy protocol following clinical assessment - not as a default add-on

References

Arroyo-Fernández R, Aceituno-Gómez J, Serrano-Muñoz D, Avendaño-Coy J. High-Intensity Laser Therapy for Musculoskeletal Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Medicine. 2023;12(4):1479. doi:10.3390/jcm12041479

Xie YH, Liao MX, Lam FMH, et al. The effectiveness of high-intensity laser therapy in individuals with neck pain: a systematic review and meta-analysis. Physiotherapy. 2023;121:23–36.

de la Barra Ortiz HA, Arias M, Liebano RE. A systematic review and meta-analysis of randomized controlled trials on the effectiveness of high-intensity laser therapy in the management of neck pain. Lasers in Medical Science. 2024;39(1):124.

Tang SK, Hon WL, Ip SW, Chung HY, Choi TCM. Effectiveness of high-intensity laser therapy in patients with lateral epicondylitis on the level of disability, pain, grip strength, and quality of life: a systematic review and meta-analysis. Physical Medicine and Rehabilitation International. 2023;10(1):1210.

Abdelbasset WK, Nambi G, Alsubaie SF, et al. A Randomized Comparative Study between High-Intensity and Low-Level Laser Therapy in the Treatment of Chronic Nonspecific Low Back Pain. Evidence-Based Complementary and Alternative Medicine. 2020; Article ID 1350281.

Xie YH, Liao MX, Lam FMH, et al. Response to Comments on: "The effectiveness of high-intensity laser therapy in individuals with neck pain: a systematic review and meta-analysis." Physiotherapy. 2024;122:82–83.

Reviewed by the RheCore Physiotherapy Team, St Kilda. Last reviewed: July 2026.

Call to Action

If you are managing a patient with a chronic musculoskeletal condition and would like to discuss whether HILT-integrated physiotherapy is appropriate, contact the RheCore team directly. We welcome referral conversations with GPs, orthopaedic surgeons and allied health practitioners.